23Andme Holding Co Stock Price, News & Analysis

23andMe Holding Co. (Nasdaq: ME), now known as Chrome Holding Co. according to SEC filings, has historically operated as a genetics-led consumer healthcare, biotechnology, and research company. Across multiple press releases, the company describes itself as a human genetics company with a mission to help people access, understand, and benefit from the human genome, and as a genetics-led consumer healthcare and research or biopharmaceutical company empowering a healthier future.

Through its consumer-facing business, 23andMe has offered personal genetics services that provide individuals with insights into their ancestry, genetic makeup, and health-related traits. Earlier descriptions note that the company has used DNA analysis technologies and web-based interactive tools to help individuals understand their own genetic information. Over time, the company has emphasized genetics-led preventive health, subscription-based premium memberships, and research participation by customers who choose to opt in.

In its health-focused offerings, 23andMe has developed genetic reports and lab tests for various conditions and traits. For example, the company has launched reports for 23andMe+ Premium members on topics such as osteoporosis and homocysteine (MTHFR-related) levels, using approaches like polygenic risk scores based on large-scale genetic and phenotypic data contributed by consented research participants. Some of these reports are paired with optional lab tests offered through 23andMe Labs for customers who want to further investigate specific biomarkers.

On the research and biopharma side, 23andMe has built what it describes as a large genetic and phenotypic research database derived from customers who have consented to participate in research. The company has highlighted that this database supports genome-wide association studies and collaborations with biopharmaceutical partners. Offerings such as Discover23 provide authorized collaborators with access to analysis-ready GWAS results within a Trusted Research Environment, allowing them to explore associations between genetic variants and disease-related phenotypes using aggregated, de-identified data.

23andMe has also entered into strategic research collaborations with drug development companies. For instance, a collaboration with Mirador Therapeutics focuses on using aggregated, de-identified genetic and phenotypic data from the 23andMe research database to support precision medicines for immunology and inflammation-related diseases. The company has stated that insights from its database have contributed to multiple drug discovery programs, clinical-stage assets, and numerous scientific publications.

In addition to genetics and research, 23andMe has had a telehealth and preventive health component. Public disclosures describe a telehealth business under the Lemonaid Health brand, providing telehealth services such as medical care, pharmacy fulfillment, and lab and test ordering. The company has also discussed a comprehensive longevity service that combines genetic sequencing, periodic lab tests, and clinicians trained in genetics-informed preventive care, as well as telehealth offerings such as GLP-1 weight loss memberships on the Lemonaid Health platform.

Corporate restructuring and Chapter 11 proceedings

According to multiple SEC filings and press releases, on March 23, 2025, 23andMe Holding Co. and certain subsidiaries filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Eastern District of Missouri. The company has stated that it initiated these proceedings to facilitate a court-supervised sale process intended to maximize the value of its business and address operational and financial challenges, including liquidity concerns and legal and leasehold liabilities.

During the Chapter 11 process, the company obtained approval for debtor-in-possession financing and sought authorization to sell substantially all of its assets. SEC filings report that, pursuant to an Asset Purchase Agreement, TTAM Research Institute, a California nonprofit public benefit corporation affiliated with a company co-founder, agreed to acquire substantially all of the debtors’ assets, excluding certain telehealth assets, for a cash purchase price plus assumption of specified liabilities. A subsequent Form 8-K notes that on July 14, 2025, the company and TTAM consummated this transaction.

Later SEC filings describe that the corporate entity formerly known as 23andMe Holding Co. changed its name to Chrome Holding Co. through a certificate of amendment filed in Delaware. The filings also explain that, following the asset sale, the debtors have been working toward winding down their estates and concluding the Chapter 11 cases through a proposed plan of reorganization. That proposed plan contemplates funding distributions with proceeds from asset sales, cash on hand, and other sources, and it outlines the treatment of various classes of claims and interests, including holders of the former holding company’s equity.

Filings repeatedly caution that trading in the company’s Class A common stock during the Chapter 11 cases is highly speculative and that trading prices may bear little or no relationship to any recovery for equity holders. As of the described filings, the Chapter 11 cases remain pending, and the company has indicated that further information about distributions, if any, would be provided at a later time.

Privacy, research participation, and data use

Across its public communications, 23andMe has consistently emphasized customer data privacy and research consent. The company states that customers have the option to consent to participate in research overseen by an independent Institutional Review Board, and that only data from customers who choose to opt in is used for research and collaboration activities. It has also described processes where personal identifiers such as names and contact details are stored separately from genetic and self-reported information, with research activities using data that has been stripped of personal identifiers.

In the context of its Chapter 11 proceedings and sale process, the company has highlighted that its existing consumer privacy policies remain in place and that any potential buyer of assets involving customer data must agree to comply with the company’s privacy policy and applicable law. Court-approved bidding procedures require qualified bidders to accept these privacy-related conditions, and any sale involving customer data is subject to court oversight and regulatory review.

Business focus and segments

Based on the company’s own descriptions in press releases and filings, 23andMe has focused on several related areas:

• Consumer genetics and preventive health – personal genetic testing and health reports, premium memberships, and services that combine genetic insights with health information.
• Research and data collaborations – use of a large, consented genetic and phenotypic database to conduct GWAS and support external biopharma research through offerings such as Discover23.
• Biopharmaceutical and therapeutics-related activities – drug discovery programs and collaborations, including work in immunology and inflammation, and historical therapeutics operations that the company has disclosed as discontinued.
• Telehealth and digital health services – telehealth services, pharmacy fulfillment, and lab test ordering under the Lemonaid Health business, and genetics-informed preventive care offerings.

In financial disclosures, the company has noted that it has shifted to operating as a single segment after closing substantially all operations in its former Therapeutics operating segment, and that it has implemented workforce reductions and other cost-cutting measures. It has also disclosed concerns about liquidity and substantial doubt about its ability to continue as a going concern prior to the Chapter 11 filing, and has described efforts to explore strategic alternatives, including potential sales and restructurings.

Historical background

A prior business description notes that 23andMe was founded in 2006 as a personal genetics company using DNA analysis technologies and web-based tools to help individuals understand their genetic information. Over time, the company’s self-description evolved to emphasize genetics-led consumer healthcare, preventive health, research, and biopharmaceutical collaborations, while maintaining a focus on enabling individuals and researchers to gain insights from human genetic data.

Key considerations for ME stock

Investors researching the ME ticker should be aware of several points reflected in the company’s public disclosures and SEC filings:

• The corporate entity associated with the ME ticker has entered Chapter 11 proceedings and has sold substantially all of its assets to a nonprofit research institute.
• The holding company has changed its name from 23andMe Holding Co. to Chrome Holding Co.
• The Chapter 11 plan process, including distributions to creditors and holders of equity interests, remains subject to court approval and other conditions.
• The company has explicitly cautioned that trading in its common stock during the Chapter 11 cases is highly speculative and that trading prices may not reflect any eventual recovery for shareholders.

Because of these developments, the ME ticker represents a company undergoing court-supervised restructuring and wind-down activities rather than an ongoing operating business holding the 23andMe consumer genetics and research platform assets, which have been sold to 23andMe Research Institute under the terms described in SEC filings.